The US market for Hemostats and Sealants continued back toward its pre-pandemic levels, gaining +20.0% QoQ and up +1.1% YoY. For FY20, the market declined, as COVID-19 delayed procedures in Q220 proved too much to overcome.
As the US Healthcare system learned to navigate the new normal and elective procedures continued their return toward COVID-19 levels, the US Hemostats and Sealants market finally exceeded pre-pandemic levels, up +1.1% YoY according to SmartTRAK Financial Dashboard. However, for the year the market was down as Q220’s delayed procedures proved too much to overcome.
Among the many topics covered in the comprehensive Q420/FY20 US Hemostats and Sealants Market Recap* are:
- Complete US Hemostats & Sealants Market Overview
- Companies' Revenues and Market Shares
- US Hemostats and Sealants Market Exceeds Pre-Pandemic Level
- Thrombin Hemostats Pull Ahead
- Fibrin Sealants Lead The Recovery
- Important Q420 US Hemostats and Sealants Events
Approximately, half of the companies in the market experienced losses for the quarter, though Ethicon* managed a +4.6% YoY gain in Q420 and Integra eked out a +2.2% YoY gain. For the full year, all manufacturers saw revenue declines ranging from ...
Read the entire Q420/FY20 US Hemostats and Sealants Market Recap including news, data, charts, company revenues, shares and analysis*
*The entire article and the links can only be viewed by SmartTRAK subscribers to this module. For more information on how to receive a demo and subscribe, please click the button below.
SmartTRAK is a comprehensive, easy-to-use, business intelligence solution that networks an entire organization with real-time market data and analysis. Used by the 15 top Advanced Wound Care companies and 8 of the 10 top Orthopedic companies, SmartTRAK transforms the delivery of healthcare business information into a cost-effective solution for life science corporations to increase proficiency, improve productivity and reduce cost.